Welcome to our dedicated page for CIBUS SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cibus, Inc. (Nasdaq: CBUS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Cibus’ operations as an agricultural technology company that develops and licenses gene-edited plant traits to seed companies.
Through its recent Forms 8-K, Cibus has reported a range of material events, such as quarterly financial results and business updates, workforce reduction decisions, and the appointment of key executives and directors. For example, filings describe the appointment of a Chief Financial Officer under an executive employment agreement, the election of new board members with experience in technology, agriculture and finance, and actions to streamline the business by consolidating facilities and reducing headcount.
These filings also confirm that Cibus’ Class A common stock, with par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol CBUS. Investors reviewing the filings can see how the company describes its focus on productivity traits for major row crops, its reliance on licensing and royalty arrangements, and its assessment of risks and strategic alternatives as referenced in its periodic reports.
On Stock Titan, Cibus filings are supplemented with AI-powered summaries that help explain the key points of lengthy documents, such as current reports on Form 8-K or sections of annual and quarterly reports. Users can quickly identify items related to executive changes, cost structure adjustments, or updates to trait development programs, and then drill down into the full text for more detail. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to track CBUS regulatory disclosures, including insider-related items reported on Form 4 and the narrative and risk discussions contained in Forms 10-K and 10-Q.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 7,319,174 Cibus Inc. Class A common shares, representing 13.9% of the class as of December 31, 2025.
FMR LLC holds sole voting and dispositive power over these shares. Abigail P. Johnson is a separate reporting person, with sole dispositive power over the same 7,319,174 shares but no voting power. The filing states the position is held in the ordinary course of business and not to influence control of Cibus.
Within this stake, Fidelity Growth Company Commingled Pool held 3,555,164 Cibus Class A shares, equal to 6.7% of the outstanding class at December 31, 2025. The filing is signed on behalf of both FMR LLC and Abigail P. Johnson under previously granted powers of attorney.
Cibus, Inc. director Jean-Pierre Jules Lehmann reported buying 666,666 shares of Class A common stock at $1.50 per share in an underwritten public offering that closed on January 30, 2026. After the purchase, he directly owned 699,156 shares and was deemed to beneficially own an additional 1,687,071 shares held by JPL Investments, SA. The transaction was approved by Cibus, Inc.’s board of directors under Rule 16b-3.
Cibus, Inc. director and 10% owner Rory B. Riggs purchased 333,333 shares of Class A Common Stock at $1.50 per share in a firm commitment underwritten public offering that closed on January 30, 2026. The purchase was approved by the board under Rule 16b-3. Following this transaction, he directly beneficially owned 14,916,640 shares, with additional indirect holdings of 23,807 shares held by the Rory Riggs Family Trust, where he is trustee with sole voting and dispositive power, and 20,974 shares held by his spouse.
Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for a public offering of 13,333,333 shares of Class A common stock at
Members of the board of directors will purchase 1,000,000 shares at the offering price, and directors, executive officers and the company agreed to a 60-day lock-up on additional sales, subject to limited exceptions. BTIG will receive a 6.25% underwriting discount and reimbursement of documented expenses up to
Cibus, Inc. is conducting a primary underwritten offering of 13,333,333 shares of Class A common stock at $1.50 per share, with gross proceeds of about $20.0 million and estimated net proceeds of approximately $17.8 million before any exercise of the underwriter’s option for 1,999,999 additional shares.
The company plans to use the cash mainly for working capital and general corporate purposes, including further development of its weed management traits in Rice and payment of accrued advisory fees, including about $2.4 million owed to Ducera. Members of the board are purchasing 999,999 shares at the public price, and CBUS remains listed on Nasdaq.
Cibus highlights significant dilution: its net tangible book value was $(4.04) per share as of September 30, 2025, and investors in this deal face immediate dilution of about $4.46 per share. The company had $23.9 million in cash and cash equivalents and $20.6 million in current liabilities as of that date, is targeting annual net cash usage of roughly $30 million in 2026, and warns that it still needs additional financing and could ultimately be forced to wind down through bankruptcy, potentially leaving shareholders with little or no recovery.
Cibus, Inc. filed an update describing its business focus and cost-cutting steps made alongside an underwritten offering. The agricultural biotechnology company develops gene-edited plant traits it licenses to seed companies for per‑acre royalties, targeting productivity, sustainability, and yield improvements.
The company is prioritizing herbicide-tolerant weed management traits for Rice, estimating potential annual accessible royalties of over $200 million in Latin America and the United States, and additional royalty opportunities in Asia and India. Management’s longer-term goal is to address about 200 million of the roughly 400 million global rice acres.
Cibus is also advancing sustainable ingredients programs, including a yeast fermentation biofragrance line that management believes could generate $20–40 million in annual revenue over time. Through 2025 it streamlined operations, including a workforce reduction completed by December 31, 2025, and expects these actions to reduce annual net cash usage to about $30 million or less during 2026 while it consolidates core operations in San Diego and concentrates spending on Rice programs.
Cibus, Inc. plans an underwritten public offering of Class A common stock on Nasdaq to raise cash for operations and its rice weed-management trait programs. Board members may buy up to approximately $1.5 million of shares at the public price, and BTIG is the sole bookrunner with a 30‑day option to purchase additional shares.
Cibus highlights significant going concern risks. As of September 30, 2025, it held $23.9 million in cash and cash equivalents against $20.6 million in current liabilities, and it is targeting annual net cash usage of about $30 million or less during 2026 after restructuring and workforce reductions.
The company is focusing capital on herbicide-tolerant rice traits, which management believes could ultimately support annual accessible royalties of over $200 million in initial markets, while pursuing partner-funded programs in biofragrances and lauric oils. A special board committee is exploring strategic alternatives, including financings, business combinations, asset sales and licensing, and warns that failure to secure sufficient capital could lead to a wind-down in which shareholders may lose most or all of their investment.
Cibus, Inc. (CBUS) reported an equity award to a company director. On 11/05/2025, the director received a stock option45,627 shares of Class A common stock at an exercise price of $1.32 per share. The option becomes exercisable on 05/22/2026 and expires on 11/05/2035, with no purchase price paid for the option itself. Following this grant, the director beneficially owns 45,627 derivative securities directly.
The option vests, subject to continued board service, on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting. Any remaining unvested portion will fully vest if a defined Triggering Event under the company’s 2017 Omnibus Incentive Plan occurs while the director continues to serve.
Cibus, Inc. filed an initial ownership report for director Craig Wichner. The Form 3 indicates that, as of the event date of 11/05/2025, he beneficially owns 0 shares of Cibus Class A Common Stock in direct form. The filing also shows no reportable derivative securities, meaning there are no listed options, warrants, or other convertible instruments tied to Cibus stock for this reporting person at this time.
Cibus, Inc. filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Revenue was $615 thousand for the quarter and $2.6 million year‑to‑date, reflecting limited current commercialization. Quarterly net loss was $24.3 million; year‑to‑date net loss was $100.3 million.
Cash and cash equivalents were $23.9 million as of September 30, 2025, against $20.6 million in current liabilities. Management states that additional capital will be needed within a year to support plans. The company raised net proceeds of approximately $21.4 million in January 2025 and $25.0 million in June 2025 follow‑on offerings and terminated its prior ATM facility without 2025 sales.
Year‑to‑date operating expenses totaled $77.5 million, including a $20.9 million goodwill impairment recognized in Q1. A July workforce reduction of ~34 roles incurred $0.2 million in severance in Q3. As of November 10, 2025, the company reported 54,283,111 shares outstanding across Class A and Class B.